Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI

BACKGROUND: To date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we investigated whether a single dose of a monoaminergic drug (methylphenidate) impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Leijenaar, Jolien F., Groeneveld, Geert Jan, Klaassen, Erica S., Leeuwis, Anna E., Scheltens, Philip, Weinstein, Henry C., van Gerven, Joop M. A., Barkhof, Frederik, van der Flier, Wiesje M., Prins, Niels D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947990/
https://www.ncbi.nlm.nih.gov/pubmed/31910895
http://dx.doi.org/10.1186/s13195-019-0567-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947990/
https://www.ncbi.nlm.nih.gov/pubmed/31910895
http://dx.doi.org/10.1186/s13195-019-0567-z

Ejemplares similares